Vol 9, No 3 (2018)
Review paper
Published online: 2018-10-17
AA amyloidosis - causes, diagnostics, therapeutic options
Hematologia 2018;9(3):173-180.
Abstract
AA amyloidosis is a complication of chronic diseases associated with the activation of acute phase reactants. The precursor of amyloid is the serum amyloid A. The kidneys are the most frequently involved, but amyloid can be deposited in any internal organ. AA amyloidosis often develops after many years of chronic illness, but its occurrence is a poor prognostic factor. Untreated leads to renal failure. For diagnosis of AA amyloidosis, histopathological confirmation is necessary. Staining with Congo red is a standard diagnostic test. Aspiration of abdominal fat is the preferred way to obtain the material for diagnostic testing. Normalization of inflammatory parameters and, as a consequence, the lack of the precursor of the deposited amyloid is a prerequisite for inhibiting the progression of the disease. In order to control inflammation, intensive treatment of the underlying disease is necessary. Initial data, in small groups of patients, indicate the benefits of interleukin 1 and 6 inhibitors.
Keywords: Amyloidosis AAserum amyloid Aautoinflammatory syndromesinterleukin 1anakinratocilizumab
References
- Parmelee DC, Titani K, Ericsson LH, et al. Amino acid sequence of amyloid-related apoprotein (apoSAA1) from human high-density lipoprotein. Biochemistry. 1982; 21(14): 3298–3303.
- Jayaraman S, Gantz DL, Haupt C, et al. Serum amyloid A forms stable oligomers that disrupt vesicles at lysosomal pH and contribute to the pathogenesis of reactive amyloidosis. Proc Natl Acad Sci U S A. 2017; 114(32): E6507–E6515.
- Kisilevsky R, Manley PN. Acute-phase serum amyloid A: perspectives on its physiological and pathological roles. Amyloid. 2012; 19(1): 5–14.
- Real de Asúa D, Costa R, Galván JM, et al. Systemic AA amyloidosis: epidemiology, diagnosis, and management. Clin Epidemiol. 2014; 6: 369–377.
- Lane T, Loeffler JM, Rowczenio DM, et al. AA amyloidosis complicating the hereditary periodic fever syndromes. Arthritis Rheum. 2013; 65(4): 1116–1121.
- Zhu LC, Sidhu GS, Yee HT, et al. AA-type amyloidosis associated with non-Hodgkin's lymphoma: a case report. Hum Pathol. 2004; 35(8): 1041–1044.
- Rowczenio DM, Pathak S, Arostegui JI, et al. Molecular genetic investigation, clinical features, and response to treatment in 21 patients with Schnitzler syndrome. Blood. 2018; 131(9): 974–981.
- Honda A, Kakihana K, Mori J, et al. Gastrointestinal AA amyloidosis following allogeneic hematopoietic stem cell transplant in a patient with chronic myelogenous leukemia. Leuk Lymphoma. 2013; 54(8): 1794–1796.
- Tajima S, Ushijima T, Matuya S, et al. AA-type amyloidosis in association with non-Hodgkin's lymphoma following CMV viremia: Autopsy case. Pathol Int. 2010; 60(3): 222–227.
- Piskin O, Alacacioglu I, Ozkal S, et al. A patient with diffuse large B-cell non-Hodgkin's lymphoma and AA type amyloidosis. J BUON. 2008; 13(1): 113–116.
- Manwani R, Wrench D, Wechalekar A, et al. Successful treatment of systemic AA amyloidosis associated with underlying Hodgkin lymphoma. Br J Haematol. 2018; 182(5): 619.
- Simms RW, Prout MN, Cohen AS. The epidemiology of AL and AA amyloidosis. Baillieres Clin Rheumatol. 1994; 8(3): 627–634.
- Girnius S, Dember L, Doros G, et al. The changing face of AA amyloidosis: a single center experience. Amyloid. 2011; 18(Suppl 1): 226–228.
- Gillmore JD, Lovat LB, Persey MR, et al. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein. Lancet. 2001; 358(9275): 24–29.
- Lachmann HJ, Goodman HJB, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Engl J Med. 2007; 356(23): 2361–2371.
- Prakash J, Brojen T, Rathore SS, et al. The changing pattern of renal amyloidosis in Indian subcontinent: two decades of experience from a single center. Ren Fail. 2012; 34(10): 1212–1216.
- Lane T, Pinney JH, Gilbertson JA, et al. Changing epidemiology of AA amyloidosis: clinical observations over 25 years at a single national referral centre. Amyloid. 2017; 24(3): 162–166.
- Harris M, Brathwaite R, Scott J, et al. Drawing attention to a neglected injecting-related harm: a systematic review of AA amyloidosis among people who inject drugs. Addiction. 2018; 113(10): 1790–1801.
- Blank N, Hegenbart U, Lohse P, et al. Familial Mediterranean fever in Germany: clinical presentation and amyloidosis risk. Scand J Rheumatol. 2013; 42(1): 52–58.
- Roztropowicz-Denisiewicz K, Małdyk E, Wagner T. Amyloidosis in juvenile rheumatic arthritis. Ped Pol. 1968; 43: 3–11.
- Filipowicz-Sosnowska AM, Roztropowicz-Denisiewicz K, Rosenthal CJ, et al. The amyloidosis of juvenile rheumatoid arthritis – comparative studies in Polish and American children. I. Levels of serum SAA protein. Arthritis Rheum. 1978; 21(6): 699–703.
- Wiland P, Wojtala R, Goodacre J, et al. The prevalence of subclinical amyloidosis in Polish patients with rheumatoid arthritis. Clin Rheumatol. 2004; 23(3): 193–198.
- Ciszek M, Kisiel B, Czerwinski J, et al. Kidney Transplant Recipients With Rheumatic Diseases: Epidemiological Data From the Polish Transplant Registries 1998–2015. Transplant Proc. 2018; 50(6): 1654–1657.
- Gómez-Casanovas E, Sanmartí R, Solé M, et al. The clinical significance of amyloid fat deposits in rheumatoid arthritis: a systematic long-term followup study using abdominal fat aspiration. Arthritis Rheum. 2001; 44(1): 66–72, doi: 10.1002/1529-0131(200101)44:1<66::AID-ANR10>3.0.CO;2-H.
- Koivuniemi R, Paimela L, Suomalainen R, et al. Amyloidosis as a cause of death in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2008; 26(3): 408–413.
- Touitou I, Sarkisian T, Medlej-Hashim M, et al. International Study Group for Phenotype-Genotype Correlation in Familial Mediterranean Fever. Country as the primary risk factor for renal amyloidosis in familial Mediterranean fever. Arthritis Rheum. 2007; 56(5): 1706–1712.
- Aganna E, Hawkins PN, Ozen S, et al. Allelic variants in genes associated with hereditary periodic fever syndromes as susceptibility factors for reactive systemic AA amyloidosis. Genes Immun. 2004; 5(4): 289–293.
- Moriguchi M, Terai C, Koseki Y, et al. Influence of genotypes at SAA1 and SAA2 loci on the development and the length of latent period of secondary AA-amyloidosis in patients with rheumatoid arthritis. Hum Genet. 1999; 105(4): 360–366.
- Nakamura T, Higashi S, Tomoda K, et al. Significance of SAA1.3 allele genotype in Japanese patients with amyloidosis secondary to rheumatoid arthritis. Rheumatology (Oxford). 2006; 45(1): 43–49.
- Nakamura T. Clinical strategies for amyloid A amyloidosis secondary to rheumatoid arthritis. Mod Rheumatol. 2008; 18(2): 109–118.
- Booth DR, Booth SE, Gillmore JD, et al. SAA1 alleles as risk factors in reactive systemic AA amyloidosis. Amyloid. 1998; 5(4): 262–265.
- Gershoni-Baruch R, Brik R, Zacks N, et al. The contribution of genotypes at the MEFV and SAA1 loci to amyloidosis and disease severity in patients with familial Mediterranean fever. Arthritis Rheum. 2003; 48(4): 1149–1155.
- Utku U, Dilek M, Akpolat I, et al. SAA1 alpha/alpha alleles in Behçet's disease related amyloidosis. Clin Rheumatol. 2007; 26(6): 927–929.
- Westermark GT, Sletten K, Westermark P. Massive vascular AA-amyloidosis: a histologically and biochemically distinctive subtype of reactive systemic amyloidosis. Scand J Immunol. 1989; 30(5): 605–613.
- Hiki Y, Horii A, Kokubo T, et al. A case of rheumatoid arthritis with renal tubular amyloidosis. Nephron. 1994; 68(3): 394–395.
- Kuroda T, Tanabe N, Hasegawa E, et al. Significant association between renal function and area of amyloid deposition in kidney biopsy specimens in both AA amyloidosis associated with rheumatoid arthritis and AL amyloidosis. Amyloid. 2017; 24(2): 123–130.
- Systemic consequences of the inflammatory process: amyloidosis, anaemia, atherosclerosis. https://www.eular.org/sysModules/sysFiles/ckeditor_4/plugins/doksoft_uploader/userfiles/Module%20titles%20list%202018_Final.pdf (24.09.2018).
- Ozawa M, Komatsuda A, Ohtani H, et al. Long-term prognosis of AL and AA renal amyloidosis: a Japanese single-center experience. Clin Exp Nephrol. 2017; 21(2): 212–227.
- Hazenberg B, Bijzet J, Limburg P, et al. Diagnostic performance of amyloid A protein quantification in fat tissue of patients with clinical AA amyloidosis. Amyloid. 2009; 14(2): 133–140.
- van Gameren II, Hazenberg BPC, Bijzet J, et al. Diagnostic accuracy of subcutaneous abdominal fat tissue aspiration for detecting systemic amyloidosis and its utility in clinical practice. Arthritis Rheum. 2006; 54(6): 2015–2021.
- Caporali R, Bonacci E, Epis O, et al. Safety and usefulness of minor salivary gland biopsy: retrospective analysis of 502 procedures performed at a single center. Arthritis Rheum. 2008; 59(5): 714–720.
- Bély M, Apáthy A. Histochemical and immunohistochemical differential diagnosis of amyloidosis – a brief illustrated essay and personal experience with Romhányi's method. Amyloid. 2000; 7(3): 212–217.
- Sipe JD, Benson MD, Buxbaum JN, et al. Amyloid fibril protein nomenclature: 2010 recommendations from the nomenclature committee of the International Society of Amyloidosis. Amyloid. 2010; 17(3–4): 101–104.
- Shah PL, Gillmore JD, Copley SJ, et al. The importance of complete screening for amyloid fibril type and systemic disease in patients with amyloidosis in the respiratory tract. Sarcoidosis Vasc Diffuse Lung Dis. 2002; 19(2): 134–142.
- Hawkins PN, Pepys MB. Imaging amyloidosis with radiolabelled SAP. Eur J Nucl Med. 1995; 22(7): 595–599.
- Marinaki S, Skalioti C, Boletis JN. Colchicine in Renal Diseases: Present and Future. Curr Pharm Des. 2018; 24(6): 675–683.
- Esatoglu SN, Hatemi G, Ugurlu S, et al. Long-term follow-up of secondary amyloidosis patients treated with tumor necrosis factor inhibitor therapy: A STROBE-compliant observational study. Medicine (Baltimore). 2017; 96(34): e7859.
- Pamuk ÖN, Kalyoncu U, Aksu K, et al. A multicenter report of biologic agents for the treatment of secondary amyloidosis in Turkish rheumatoid arthritis and ankylosing spondylitis patients. Rheumatol Int. 2016; 36(7): 945–953.
- Nakamura T, Higashi SI, Tomoda K, et al. Effectiveness of etanercept vs cyclophosphamide as treatment for patients with amyloid A amyloidosis secondary to rheumatoid arthritis. Rheumatology (Oxford). 2012; 51(11): 2064–2069.
- Trabulus S, Korkmaz M, Kaya E, et al. Canakinumab treatment in kidney transplant recipients with AA amyloidosis due to familial Mediterranean fever. Clin Transplant. 2018; 32(8): e13345.
- Varan Ö, Kucuk H, Babaoglu H, et al. Efficacy and safety of interleukin-1 inhibitors in familial Mediterranean fever patients complicated with amyloidosis. Mod Rheumatol. 2018 [Epub ahead of print]: 1–4.
- Lane T, Wechalekar AD, Gillmore JD, et al. Safety and efficacy of empirical interleukin-1 inhibition using anakinra in AA amyloidosis of uncertain aetiology. Amyloid. 2017; 24(3): 189–193.
- Ugurlu S, Hacioglu A, Adibnia Y, et al. Tocilizumab in the treatment of twelve cases with aa amyloidosis secondary to familial mediterranean fever. Orphanet J Rare Dis. 2017; 12(1): 105.
- Lane T, Gillmore JD, Wechalekar AD, et al. Therapeutic blockade of interleukin-6 by tocilizumab in the management of AA amyloidosis and chronic inflammatory disorders: a case series and review of the literature. Clin Exp Rheumatol. 2015; 33(6, Suppl 94): S46–S53.
- Courties A, Grateau G, Philippe P, et al. Club Rhumatismes Inflammation and the REGATE Registry. AA amyloidosis treated with tocilizumab: case series and updated literature review. Amyloid. 2015; 22(2): 84–92.
- Ministerstwo Zdrowia – Choroby nieonkologiczne. https://www.gov.pl/zdrowie/choroby-nieonkologiczne (24.09.2018).
- Lange U, Boss B, Teichmann J, et al. Serum amyloid A – an indicator of inflammation in ankylosing spondylitis. Rheumatol Int. 2000; 19(4): 119–122.
- Bergesio F, Ciciani AM, Manganaro M, et al. Immunopathology Group of the Italian Society of Nephrology. Renal involvement in systemic amyloidosis: an Italian collaborative study on survival and renal outcome. Nephrol Dial Transplant. 2008; 23(3): 941–951.
- Tanaka F, Migita K, Honda S, et al. Clinical outcome and survival of secondary (AA) amyloidosis. Clin Exp Rheumatol. 2003; 21(3): 343–346.
- Obici L, Perfetti V, Palladini G, et al. Clinical aspects of systemic amyloid diseases. Biochim Biophys Acta. 2005; 1753(1): 11–22.
- Perfetto F, Moggi-Pignone A, Livi R, et al. Systemic amyloidosis: a challenge for the rheumatologist. Nat Rev Rheumatol. 2010; 6(7): 417–429.
